Pletcher, A. & Shibata, M. Prostate organogenesis. Development 149, dev200394 (2022).
Dai, C., Heemers, H. & Sharifi, N. Androgen signaling in prostate cancer. Cold Spring Harb. Perspect. Med. 7, a030452 (2017).
Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).
Clocchiatti, A., Cora, E., Zhang, Y. & Dotto, G. P. Sexual dimorphism in cancer. Nat. Rev. Cancer 16, 330–339 (2016).
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B. & Haupt, Y. Sex disparities matter in cancer development and therapy. Nat. Rev. Cancer 21, 393–407 (2021).
Rubin, J. B. The spectrum of sex differences in cancer. Trends Cancer 8, 303–315 (2022).
Dotto, G. P. Gender and sex-time to bridge the gap. EMBO Mol. Med. 11, e10668 (2019).
Davey, R. A. & Grossmann, M. Androgen receptor structure, function and biology: from bench to bedside. Clin. Biochem. Rev. 37, 3–15 (2016).
Heemers, H. V. & Tindall, D. J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28, 778–808 (2007).
Kono, M. et al. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review. JAMA Oncol. 3, 1266–1273 (2017).
Shukla, G. C., Plaga, A. R., Shankar, E. & Gupta, S. Androgen receptor-related diseases: what do we know? Andrology 4, 366–381 (2016).
Matsumoto, T. et al. The androgen receptor in health and disease. Annu. Rev. Physiol. 75, 201–224 (2013).
Liu, W.-J. et al. Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer. J. Cell. Biochem. 121, 2756–2769 (2020).
Leach, D. A., Fernandes, R. C. & Bevan, C. L. Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer. Endocr. Oncol. 2, R112–R131 (2022).
Dahiya, U. R. & Heemers, H. V. Analyzing the androgen receptor interactome in prostate cancer: implications for therapeutic intervention. Cells 11, 936 (2022).
Leung, J. K. & Sadar, M. D. Non-genomic actions of the androgen receptor in prostate cancer. Front. Endocrinol. 8, 2 (2017).
Bennesch, M. A. & Picard, D. Minireview: tipping the balance: ligand-independent activation of steroid receptors. Mol. Endocrinol. 29, 349–363 (2015).
Guo, Z. et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10, 309–319 (2006).
Ueda, T., Bruchovsky, N. & Sadar, M. D. Activation of the androgen receptor N-terminal domain by interleukin-6 via mAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277, 7076–7085 (2002).
Cai, L. et al. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer. Mol. Cell 72, 341–354.e6 (2018).
Dahiya, V. & Bagchi, G. Non-canonical androgen signaling pathways and implications in prostate cancer. Biochim. Biophys. Acta Mol. Cell Res. 1869, 119357 (2022).
Thomas, P. Membrane androgen receptors unrelated to nuclear steroid receptors. Endocrinology 160, 772–781 (2019).
Hughes, I. A. et al. Androgen insensitivity syndrome. Lancet 380, 1419–1428 (2012).
Turcu, A. F., Rege, J., Auchus, R. J. & Rainey, W. E. 11-oxygenated androgens in health and disease. Nat. Rev. Endocrinol. 16, 284–296 (2020).
Marchetti, P. M. & Barth, J. H. Clinical biochemistry of dihydrotestosterone. Ann. Clin. Biochem. 50, 95–107 (2013).
Labrie, F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J. Steroid Biochem. Mol. Biol. 145, 133–138 (2015).
Pugeat, M. et al. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol. Cell. Endocrinol. 316, 53–59 (2010).
Simó, R., Sáez-López, C., Barbosa-Desongles, A., Hernández, C. & Selva, D. M. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol. Metab. 26, 376–383 (2015).
Samarkina, A. et al. Androgen receptor is a determinant of melanoma targeted drug resistance. Nat. Commun. 14, 6498 (2023). This study reveals that increased AR expression in melanoma cells is both required and sufficient to confer resistance to BRAF inhibitors through transcriptional activation mechanisms that can be targeted.
Castoria, G. et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J. Cell Biol. 161, 547–556 (2003).
Acharya, S. et al. Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer. J. Biol. Chem. 299, 102725 (2023).
Shao, C. et al. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. J. Androl. 28, 804–812 (2007).
Li, F. et al. Sex differences orchestrated by androgens at single-cell resolution. Nature 629, 193–200 (2024). This study presents a single-cell transcriptomic atlas of sex differences in mice, revealing how androgens modulate immune gene expression and cell populations.
Zhao, J., Wang, Q., Tan, A. F., Loh, C. J. L. & Toh, H. C. Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor. Front. Immunol. 15, 1416941 (2024).
Leo, J. et al. Stranger things: new roles and opportunities for androgen receptor in oncology beyond prostate cancer. Endocrinology 164, bqad071 (2023).
Dai, C. & Ellisen, L. W. Revisiting androgen receptor signaling in breast cancer. Oncologist 28, 383–391 (2023).
Chen, J. et al. The androgen receptor in bladder cancer. Nat. Rev. Urol. 20, 560–574 (2023).
Munoz, J., Wheler, J. J. & Kurzrock, R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget 6, 592–603 (2014).
Lee, D. K. & Chang, C. Expression and degradation of androgen receptor: mechanism and clinical implication. J. Clin. Endocrinol. Metab. 88, 4043–4054 (2003).
Cai, C. et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20, 457–471 (2011).
Huhtaniemi, R. et al. High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice. iScience 25, 104287 (2022).
Shiota, M., Yokomizo, A. & Naito, S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J. Mol. Endocrinol. 47, R25–R41 (2011).
Landi, M. T. et al. Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility. Nat. Genet. 52, 494–504 (2020).
Olsen, C. M., Thompson, J. F., Pandeya, N. & Whiteman, D. C. Evaluation of sex-specific incidence of melanoma. JAMA Dermatol. 156, 553–560 (2020).
Rampen, F. H. & Mulder, J. H. Malignant melanoma: an androgen-dependent tumour? Lancet 1, 562–564 (1980).
Wang, Y. et al. Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals. Oncogene 36, 1644–1654 (2017).
Ma, M. et al. Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. J. Exp. Med. 218, e20201137 (2021). The paper demonstrates that, despite heterogeneous expression, basal AR activity is required for sustained melanoma cell proliferation and tumorigenesis with the AR protein bridging transcription and transcription-coupled DNA repair.
Liu, Q. et al. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. Nat. Commun. 15, 1148 (2024).
Aguirre-Portolés, C. et al. ZIP9 is a druggable determinant of sex differences in melanoma. Cancer Res. 81, 5991–6003 (2021).
Vellano, C. P. et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606, 797–803 (2022). The study shows that female patients with melanoma had significantly better responses to BRAF–MEK-targeted therapy than male patients, and in preclinical melanoma models, elevated AR expression impaired treatment efficacy, while AR inhibition improved responses.
Yang, W. et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci. Transl. Med. 11, eaao5253 (2019).
Gan, X., Liu, Y. & Wang, X. Targeting androgen receptor in glioblastoma. Crit. Rev. Oncol. Hematol. 191, 104142 (2023).
Zalcman, N. et al. Androgen receptor: a potential therapeutic target for glioblastoma. Oncotarget 9, 19980–19993 (2018).
Zalcman, N., Gutreiman, M., Shahar, T., Weller, M. & Lavon, I. Androgen receptor activation in glioblastoma can be achieved by ligand-independent signaling through EGFR — a potential therapeutic target. Int. J. Mol. Sci. 22, 10954 (2021).
Dalin, M. G., Watson, P. A., Ho, A. L. & Morris, L. G. T. Androgen receptor signaling in salivary gland cancer. Cancers 9, 17 (2017).
Yeoh, C. C. et al. Androgen receptor in salivary gland carcinoma: a review of an old marker as a possible new target. J. Oral. Pathol. Med. 47, 691–695 (2018).
Viscuse, P. V., Price, K. A., Garcia, J. J., Schembri-Wismayer, D. J. & Chintakuntlawar, A. V. First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma — a retrospective study. Front. Oncol. 9, 701 (2019).
Matye, D., Leak, J., Woolbright, B. L. & Taylor, J. A. Preclinical models of bladder cancer: BBN and beyond. Nat. Rev. Urol. https://doi.org/10.1038/s41585-024-00885-9 (2024).
Hsu, J.-W. et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am. J. Pathol. 182, 1811–1820 (2013).
Sfakianos, J. P. et al. Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. Nat. Commun. 11, 2540 (2020).
Lopez-Beltran, A. et al. Molecular classification of bladder urothelial carcinoma using nanostring-based gene expression analysis. Cancers 13, 5500 (2021).
Altevogt, P., Sammar, M., Hüser, L. & Kristiansen, G. Novel insights into the function of CD24: a driving force in cancer. Int. J. Cancer 148, 546–559 (2021).
Chen, J. et al. Androgen receptor‐regulated circFNTA activates KRAS signaling to promote bladder cancer invasion. EMBO Rep. 21, e48467 (2020).
Sottnik, J. L. et al. Androgen receptor regulates CD44 expression in bladder cancer. Cancer Res 81, 2833–2846 (2021).
Chen, J. et al. Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling. Oncogene 39, 574–586 (2020).
Kaneko, S. & Li, X. X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci. Adv. 4, eaar5598 (2018).
Qiu, H. et al. KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer. Cancer Res 83, 814–829 (2023).
Hua, C. et al. KDM6 demethylases and their roles in human cancers. Front. Oncol. 11, 779918 (2021).
Kashiwagi, E. et al. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget 7, 49169–49179 (2016).
Ide, H. et al. FOXO1 inactivation induces cisplatin resistance in bladder cancer. Cancer Sci. 111, 3397–3400 (2020).
Chen, F., Langenstroer, P., Zhang, G., Iwamoto, Y. & See, W. A. Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. J. Urol. 170, 2009–2013 (2003).
Clocchiatti, A. et al. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. J. Clin. Invest. 128, 5531–5548 (2018). The study demonstrates that AR is a key negative regulator of stromal fibroblast activation into CAFs by parallel suppression of senescence and CAF effector genes.
Foersch, S. et al. Prognostic relevance of androgen receptor expression in renal cell carcinomas. Oncotarget 8, 78545–78555 (2017).
Cheng, B. et al. Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. Cell Death Discov. 9, 121 (2023).
You, B. et al. Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR. Oncogene 40, 1674–1689 (2021).
Huang, Q. et al. Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma. Nat. Commun. 8, 918 (2017).
Acosta-Lopez, S. et al. The androgen receptor expression and its activity have different relationships with prognosis in hepatocellular carcinoma. Sci. Rep. 10, 22046 (2020).
Zhang, L. et al. Sex steroid axes in determining male predominance in hepatocellular carcinoma. Cancer Lett. 555, 216037 (2023).
Li, Z., Tuteja, G., Schug, J. & Kaestner, K. H. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 148, 72–83 (2012).
Liu, N. et al. FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer. Cell Death Discov. 10, 172 (2024).
Feng, H. et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis. J. Clin. Invest. 121, 3159–3175 (2011).
Bolis, M. et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat. Commun. 12, 7033 (2021).
Song, H. et al. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling. EBioMedicine 35, 155–166 (2018).
Jiang, L. et al. Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma. Oncotarget 7, 36814–36828 (2016).
Jeter, C. R., Yang, T., Wang, J., Chao, H.-P. & Tang, D. G. NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells 33, 2381–2390 (2015).
Tang, J.-J. et al. Androgens drive sexual dimorphism in liver metastasis by promoting hepatic accumulation of neutrophils. Cell Rep. 39, 110987 (2022).
Harlos, C., Musto, G., Lambert, P., Ahmed, R. & Pitz, M. W. Androgen pathway manipulation and survival in patients with lung cancer. Horm. Cancer 6, 120–127 (2015).
Xia, T. et al. Androgen receptor gene methylation related to colorectal cancer risk. Endocr. Connect. 8, 979–987 (2019).
Oram, S. W., Liu, X. X., Lee, T.-L., Chan, W.-Y. & Lau, Y.-F. C. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer 6, 154 (2006).
Li, Y., Zhang, D. J., Qiu, Y., Kido, T. & Lau, Y.-F. C. The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants. Hum. Mol. Genet. 26, 901–912 (2017).
Sun, S. et al. UXT is a novel and essential cofactor in the NF-κB transcriptional enhanceosome. J. Cell Biol. 178, 231–244 (2007).
Chen, S., Chen, K., Zhang, Q., Cheng, H. & Zhou, R. Regulation of the transcriptional activation of the androgen receptor by the UXT-binding protein VHL. Biochem. J. 456, 55–66 (2013).
Gupta, A. et al. Androgen receptor activation induces senescence in thyroid cancer cells. Cancers 15, 2198 (2023).
O’Connell, T. J. et al. Androgen activity is associated with PD-L1 downregulation in thyroid cancer. Front. Cell Dev. Biol. 9, 663130 (2021).
Chou, C.-K. et al. Aberrant expression of androgen receptor associated with high cancer risk and extrathyroidal extension in papillary thyroid carcinoma. Cancers 12, 1109 (2020).
Chukkalore, D., MacDougall, K., Master, V., Bilen, M. A. & Nazha, B. Adrenocortical carcinomas: molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches. Oncologist 29, 738–746 (2024).
Berger, A. C. et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell 33, 690–705.e9 (2018).
Noel, J. C. et al. Androgen receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Int. J. Gynecol. Pathol. 27, 437–441 (2008).
Matsumoto, T. et al. Androgen promotes squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway. Cancer Med 12, 10816–10828 (2023).
Kamal, A. M. et al. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br. J. Cancer 114, 688–696 (2016).
Gibson, D. A., Simitsidellis, I., Collins, F. & Saunders, P. T. K. Evidence of androgen action in endometrial and ovarian cancers. Endocr. Relat. Cancer 21, T203–T218 (2014).
Mizushima, T. & Miyamoto, H. The role of androgen receptor signaling in ovarian cancer. Cells 8, 176 (2019).
Sun, N.-K., Huang, S.-L., Lu, H.-P., Chang, T.-C. & Chao, C. C.-K. Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: analysis of the androgen receptor. Oncotarget 6, 27065–27082 (2015).
Chen, N. & Nanda, R. Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 25, 269–270 (2024).
Collins, L. C. et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod. Pathol. 24, 924–931 (2011).
Cha, J. et al. Distribution of breast cancer molecular subtypes within receptor classifications: lessons from the I-SPY2 Trial and FLEX Registry. J. Clin. Oncol. 40, 592–592 (2022).
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) & Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011).
Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846 (2017).
Aouad, P. et al. Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. Nat. Commun. 13, 4975 (2022).
Hickey, T. E. et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat. Med. 27, 310–320 (2021).
Hosseinzadeh, L. et al. The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer. Genome Biol. 25, 44 (2024).
Scabia, V. et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nat. Commun. 13, 3127 (2022).
Ionescu, S., Nicolescu, A. C., Marincas, M., Madge, O.-L. & Simion, L. An update on the general features of breast cancer in male patients — a literature review. Diagnostics 12, 1554 (2022).
Severson, T. M. et al. Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. Nat. Commun. 9, 482 (2018).
Ni, M. et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20, 119–131 (2011).
Chia, K. M., Liu, J., Francis, G. D. & Naderi, A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13, 154–166 (2011).
Naderi, A., Chia, K. M. & Liu, J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res. 13, R36 (2011).
Farmer, P. et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660–4671 (2005).
Safarpour, D., Pakneshan, S. & Tavassoli, F. A. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am. J. Cancer Res. 4, 353–368 (2014).
Kim, J.-Y. et al. Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer. Exp. Mol. Med. 55, 1451–1461 (2023).
Choupani, E. et al. Newly developed targeted therapies against the androgen receptor in triple-negative breast cancer: a review. Pharmacol. Rev. 75, 309–327 (2023).
Lehmann, B. D. et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 16, 406 (2014).
Ben-Batalla, I., Vargas-Delgado, M. E., von Amsberg, G., Janning, M. & Loges, S. Influence of androgens on immunity to self and foreign: effects on immunity and cancer. Front. Immunol. 11, 1184 (2020).
Ozdemir, B. C. & Dotto, G. P. Sex hormones and anticancer immunity. Clin. Cancer Res. 25, 4603–4610 (2019).
Xiao, T. et al. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat. Rev. Cancer 24, 338–355 (2024).
Conforti, F. et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 19, 737–746 (2018). This meta-analysis discusses sex-related differences in the efficacy of ICIs and underscores the need for more inclusive trials.
Pala, L., De Pas, T. & Conforti, F. Boosting anticancer immunotherapy through androgen receptor blockade. Cancer Cell 40, 455–457 (2022).
Liu, Q. et al. Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. Cancer Gene Ther. 29, 1988–2000 (2022).
Kissick, H. T. et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc. Natl Acad. Sci. USA 111, 9887–9892 (2014).
Guan, X. et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606, 791–796 (2022). This work shows that AR blockade enhances the effectiveness of immune-checkpoint therapy in prostate cancer by preventing CD8+ T cell exhaustion and boosting IFNγ production.
Kwon, H. et al. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Sci. Immunol. 7, eabq2630 (2022). This study demonstrates that AR signalling promotes CD8+ T cell exhaustion through the upregulation of TCF1 in a CD8+ T cell-intrinsic manner.
Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840–855.e5 (2019).
Escobar, G., Mangani, D. & Anderson, A. C. T cell factor 1: a master regulator of the T cell response in disease. Sci. Immunol. 5, eabb9726 (2020).
Yang, C. et al. Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. Immunity 55, 1268–1283.e9 (2022). This paper implicates AR in sex-biased CD8+ T cell self-renewal versus exhaustion programmes in cancer progression and in responses to cancer immunotherapy.
Lee, J. et al. Sex-biased T-cell exhaustion drives differential immune responses in glioblastoma. Cancer Discov. 13, 2090–2105 (2023).
Walecki, M. et al. Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. Mol. Biol. Cell 26, 2845–2857 (2015).
Wu, L. et al. Role of ILC2s in solid tumors: facilitate or inhibit? Front. Immunol. 13, 886045 (2022).
Chi, L. et al. Sexual dimorphism in skin immunity is mediated by an androgen-ILC2-dendritic cell axis. Science 384, eadk6200 (2024).
Laffont, S. et al. Androgen signaling negatively controls group 2 innate lymphoid cells. J. Exp. Med. 214, 1581–1592 (2017).
Tang, M. et al. High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals. Cell Death Dis. 13, 746 (2022).
Pinho-Schwermann, M. et al. Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade. Preprint at bioRxiv https://doi.org/10.1101/2023.11.15.567201 (2023).
Becerra-Diaz, M., Song, M. & Heller, N. Androgen and androgen receptors as regulators of monocyte and macrophage biology in the healthy and diseased lung. Front. Immunol. 11, 1698 (2020).
Cioni, B. et al. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion. Nat. Commun. 11, 4498 (2020).
Chuang, K.-H. et al. Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor. J. Exp. Med. 206, 1181–1199 (2009).
Yu, X. et al. Neutrophils in cancer: dual roles through intercellular interactions. Oncogene 43, 1163–1177 (2024).
Markman, J. L. et al. Loss of testosterone impairs anti-tumor neutrophil function. Nat. Commun. 11, 1613 (2020).
Alsamraae, M. et al. Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression. Cancer Lett. 579, 216468 (2023).
Vancolen, S., Sébire, G. & Robaire, B. Influence of androgens on the innate immune system. Andrology 11, 1237–1244 (2023).
Spencer, J. B., Klein, M., Kumar, A. & Azziz, R. The age-associated decline of androgens in reproductive age and menopausal black and white women. J. Clin. Endocrinol. Metab. 92, 4730–4733 (2007).
Kaufman, J. M. & Vermeulen, A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833–876 (2005).
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123, 966–972 (2013).
Biffi, G. & Tuveson, D. A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev. 101, 147–176 (2021).
Chen, Y., McAndrews, K. M. & Kalluri, R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat. Rev. Clin. Oncol. 18, 792–804 (2021).
Davidson, S. et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat. Rev. Immunol. 21, 704–717 (2021).
Lavie, D., Ben-Shmuel, A., Erez, N. & Scherz-Shouval, R. Cancer-associated fibroblasts in the single-cell era. Nat. Cancer 3, 793–807 (2022).
Procopio, M. G. et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat. Cell Biol. 17, 1193–1204 (2015).
Bordignon, P. et al. Dualism of FGF and TGF-β signaling in heterogeneous cancer-associated fibroblast activation with ETV1 as a critical determinant. Cell Rep. 28, 2358–2372.e6 (2019).
Capolupo, L. et al. Sphingolipids control dermal fibroblast heterogeneity. Science 376, eabh1623 (2022).
Lan, C. et al. Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma. Br. J. Cancer 126, 219–227 (2022).
Wang, T. et al. Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance prometastatic phenotypes. Mol. Cancer Res. 15, 3–14 (2017).
Belle, J. I. et al. Senescence defines a distinct subset of myofibroblasts that orchestrates immunosuppression in pancreatic cancer. Cancer Discov. 14, 1324–1355 (2024).
Fan, G. et al. TSPAN8+ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. Sci. Transl. Med. 16, eadj5705 (2024).
Ye, J. et al. Senescent CAFs mediate immunosuppression and drive breast cancer progression. Cancer Discov. 14, 1302–1323 (2024).
Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174–186 (2020).
Erez, N., Truitt, M., Olson, P., Arron, S. T. & Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 17, 135–147 (2010).
Fitsiou, E., Pulido, T., Campisi, J., Alimirah, F. & Demaria, M. Cellular senescence and the senescence-associated secretory phenotype as drivers of skin photoaging. J. Invest. Dermatol. 141, 1119–1126 (2021).
Bachelor, M. A. & Bowden, G. T. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin. Cancer Biol. 14, 131–138 (2004).
Mazzeo, L. et al. ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation, bridging androgen receptor loss to AP-1 activation. Nat. Commun. 15, 1038 (2024).
Karoutas, A. & Akhtar, A. Functional mechanisms and abnormalities of the nuclear lamina. Nat. Cell Biol. 23, 116–126 (2021).
Ghosh, S. et al. Nuclear lamin A/C phosphorylation by loss of androgen receptor leads to cancer-associated fibroblast activation. Nat. Commun. 15, 7984 (2024).
Liao, C.-P. et al. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr. Relat. Cancer 24, 157–170 (2017).
Cioni, B. et al. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration. Mol. Oncol. 12, 1308–1323 (2018).
Chen, L. et al. LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation. Cancer Lett. 503, 138–150 (2021).
De Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).
Eisermann, K. & Fraizer, G. The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer. Cancers 9, 32 (2017).
Torres-Estay, V. et al. Androgen receptor in human endothelial cells. J. Endocrinol. 224, R131–R137 (2015).
Godoy, A. et al. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 149, 2959–2969 (2008).
Godoy, A. et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am. J. Physiol. Endocrinol. Metab. 300, E263–E275 (2011).
Rizk, J., Sahu, R. & Duteil, D. An overview on androgen-mediated actions in skeletal muscle and adipose tissue. Steroids 199, 109306 (2023).
Bouche, C. & Quail, D. F. Fueling the tumor microenvironment with cancer-associated adipocytes. Cancer Res 83, 1170–1172 (2023).
Alvarez-Artime, A. et al. Castration promotes the browning of the prostate tumor microenvironment. Cell Commun. Signal. 21, 267 (2023).
Doron, H., Pukrop, T. & Erez, N. A blazing landscape: neuroinflammation shapes brain metastasis. Cancer Res 79, 423–436 (2019).
Gatson, J. W. & Singh, M. Activation of a membrane-associated androgen receptor promotes cell death in primary cortical astrocytes. Endocrinology 148, 2458–2464 (2007).
Cioffi, G. et al. Sex differences in odds of brain metastasis and outcomes by brain metastasis status after advanced melanoma diagnosis. Cancers 16, 1771 (2024).
Russo, S., Scotto Di Carlo, F. & Gianfrancesco, F. The osteoclast traces the route to bone tumors and metastases. Front. Cell Dev. Biol. 10, 886305 (2022).
Farach-Carson, M. C., Lin, S.-H., Nalty, T. & Satcher, R. L. Sex differences and bone metastases of breast, lung, and prostate cancers: do bone homing cancers favor feminized bone marrow? Front. Oncol. 7, 163 (2017).
Kawano, H. et al. Suppressive function of androgen receptor in bone resorption. Proc. Natl Acad. Sci. USA 100, 9416–9421 (2003).
Pederson, L. et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc. Natl Acad. Sci. USA 96, 505–510 (1999).
Chen, J.-F., Lin, P.-W., Tsai, Y.-R., Yang, Y.-C. & Kang, H.-Y. Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy. Cells 8, 1318 (2019).
Brown, J. E. et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J. Bone Oncol. 25, 100311 (2020).
Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39 (2004).
Culig, Z. et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 81, 242–251 (1999).
Loddick, S. A. et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol. Cancer Ther. 12, 1715–1727 (2013).
Neklesa, T. et al. ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer. J. Clin. Oncol. 37, 259–259 (2019).
Gao, X. et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 40, 17–17 (2022).
Chen, Q.-H., Munoz, E. & Ashong, D. Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer. Cancers 16, 663 (2024).
Myung, J.-K. et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest. 123, 2948–2960 (2013).
Maurice-Dror, C. et al. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor N-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. Invest. New Drugs 40, 322–329 (2022).
Chen, Y. & Lan, T. N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review. Front. Pharmacol. 15, 1451957 (2024).
Bhasin, S. et al. Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat. Clin. Pract. Endocrinol. Metab. 2, 146–159 (2006).
US National Library of Medicine. ClinicialTrials.gov https://clinicaltrials.gov/study/NCT02689427 (2023).
Lim, B. et al. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”. Cell Rep. Med. 5, 101595 (2024).
US National Library of Medicine. ClinicialTrials.gov https://www.clinicaltrials.gov/study/NCT02007512 (2024).
Krop, I. et al. A randomized placebo controlled phase ii trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer. Clin. Cancer Res. 26, 6149–6157 (2020).
Palmieri, C. et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 25, 317–325 (2024). This phase II trial demonstrates that enobosarm, a selective AR modulator, shows anti-tumour activity and clinical benefit in women in postmenopause with ER-positive, HER2-negative and AR-positive advanced breast cancer, supporting further investigation of AR activation as a therapeutic strategy.
Conforti, F. et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J. Natl Cancer Inst. 111, 772 (2019).
Powles, T. et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat. Med. 28, 144–153 (2022).
Venkatachalam, S., McFarland, T. R., Agarwal, N. & Swami, U. Immune checkpoint inhibitors in prostate cancer. Cancers 13, 2187 (2021).
US National Library of Medicine. ClinicialTrials.gov https://www.clinicaltrials.gov/study/NCT02971761 (2022).
Yuan, Y. et al. A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist 26, 99–e217 (2021).
US National Library of Medicine. ClinicialTrials.gov https://clinicaltrials.gov/study/NCT03650894 (2024).
US National Library of Medicine. ClinicialTrials.gov https://www.clinicaltrials.gov/study/NCT03942653 (2024).
Iwashyna, T. J. & McPeake, J. Choosing outcomes for clinical trials: a pragmatic perspective. Curr. Opin. Crit. Care 24, 428–433 (2018).
Kensler, K. H. et al. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98. Breast Cancer Res. 21, 30 (2019).
Hirko, K. A. et al. The impact of race and ethnicity in breast cancer — disparities and implications for precision oncology. BMC Med. 20, 72 (2022).
Siu, D. H. W. et al. Framework for the use of external controls to evaluate treatment outcomes in precision oncology trials. JCO Precis. Oncol. 8, e2300317 (2024).
Fushimi, C. et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann. Oncol. 29, 979–984 (2018).
Liu, H.-H. et al. Evolving personalized therapy for castration-resistant prostate cancer. BioMedicine 4, 2 (2014).
Ozdemir, B. C. & Dotto, G. P. Racial differences in cancer susceptibility and survival: more than the color of the skin? Trends Cancer 3, 181–197 (2017).
Zavala, V. A. et al. Cancer health disparities in racial/ethnic minorities in the United States. Br. J. Cancer 124, 315–332 (2021).
Wang, B.-D. et al. Androgen receptor-target genes in African American prostate cancer disparities. Prostate Cancer 2013, 763569 (2013).
Ellis, L. & Nyborg, H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids 57, 72–75 (1992).
Gaston, K. E., Kim, D., Singh, S., Ford, O. H. & Mohler, J. L. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J. Urol. 170, 990–993 (2003).
Edwards, A., Hammond, H. A., Jin, L., Caskey, C. T. & Chakraborty, R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12, 241–253 (1992).
Sartor, O., Zheng, Q. & Eastham, J. A. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 53, 378–380 (1999).
Giovannucci, E. et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA 94, 3320–3323 (1997).
Zhang, B. et al. Harnessing artificial intelligence to improve clinical trial design. Commun. Med. 3, 191 (2023).
Shamseddin, M. et al. Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. EMBO Mol. Med. 13, e14314 (2021).
Berner, A. M. Improving understanding of cancer in the gender diverse population. Nat. Rev. Cancer 21, 537–538 (2021).
Vera-Badillo, F. E. et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J. Natl Cancer Inst. 106, djt319 (2014).
Wang, X. et al. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer. Endocr. Relat. Cancer 27, 199–208 (2020).
Bozovic-Spasojevic, I. et al. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin. Cancer Res. 23, 2702–2712 (2017).
Choi, J. E., Kang, S. H., Lee, S. J. & Bae, Y. K. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann. Surg. Oncol. 22, 82–89 (2015).
Shi, Z. et al. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy. Discov. Oncol. 14, 49 (2023).
Wang, C. et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget 7, 46482–46491 (2016).
Xu, M. et al. Prognostic significance of androgen receptor expression in triple negative breast cancer: a systematic review and meta-analysis. Clin. Breast Cancer 20, e385–e396 (2020).
Boon, E. et al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int. J. Cancer 143, 758–766 (2018).
Xu, B., Dogan, S., Haroon Al Rasheed, M. R., Ghossein, R. & Katabi, N. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Hum. Pathol. 93, 30–36 (2019).
Atef, A., El-Rashidy, M. A., Elzayat, S. & Kabel, A. M. The prognostic value of sex hormone receptors expression in laryngeal carcinoma. Tissue Cell 57, 84–89 (2019).
Fei, M., Zhang, J., Zhou, J., Xu, Y. & Wang, J. Sex-related hormone receptor in laryngeal squamous cell carcinoma: correlation with androgen estrogen-ɑ and prolactin receptor expression and influence of prognosis. Acta Otolaryngol. 138, 66–72 (2018).
R, S. et al. Expression of sex hormones in oral squamous cell carcinoma: a systematic review on immunohistochemical studies. Cureus 14, e25384 (2022).
Adnan, Y. et al. Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: correlation with overall survival, disease-free survival and 10-year survival in a high-risk population. PLoS One 17, e0267300 (2022).
Gan, L. et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer 12, 566 (2012).
Tang, W. et al. Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. Oncotarget 8, 40765–40777 (2017).
Albasri, A. M. & Elkablawy, M. A. Clinicopathological and prognostic significance of androgen receptor overexpression in colorectal cancer. Experience from Al-Madinah Al-Munawarah, Saudi Arabia. Saudi Med. J. 40, 893–900 (2019).
Jönsson, J.-M. et al. Sex steroid hormone receptor expression affects ovarian cancer survival. Transl. Oncol. 8, 424–433 (2015).
van Kruchten, M. et al. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol. Oncol. 138, 634–639 (2015).
Wu, X. et al. The clinicopathological significance and prognostic value of androgen receptor in endometrial carcinoma: a meta-analysis. Front. Oncol. 12, 905809 (2022).
Zhao, H., Leppert, J. T. & Peehl, D. M. A protective role for androgen receptor in clear cell renal cell carcinoma based on mining TCGA data. PLoS One 11, e0146505 (2016).
Zhu, G. et al. The expression and evaluation of androgen receptor in human renal cell carcinoma. Urology 83, 510.e19-24 (2014).
Szabados, B. et al. Androgen receptor expression is a predictor of poor outcome in urothelial carcinoma. Front. Urol. 2, https://doi.org/10.3389/fruro.2022.863784 (2022).
Tripathi, A. & Gupta, S. Androgen receptor in bladder cancer: a promising therapeutic target. Asian J. Urol. 7, 284–290 (2020).
Vizoso, F. J. et al. Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma. World J. Gastroenterol. 13, 3221–3227 (2007).
Zhang, H. et al. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology 67, 2271–2286 (2018).
Grant, L. et al. Androgen receptor and Ki67 expression and survival outcomes in non-small cell lung cancer. Horm. Cancer 9, 288–294 (2018).
Zhao, N. et al. Androgen receptor, although not a specific marker for, is a novel target to suppress glioma stem cells as a therapeutic strategy for glioblastoma. Front. Oncol. 11, 616625 (2021).
Simińska, D. et al. Androgen receptor expression in the various regions of resected glioblastoma multiforme tumors and in an in vitro model. Int. J. Mol. Sci. 23, 13004 (2022).
Park, H. S. et al. Expression of DBC1 and androgen receptor predict poor prognosis in diffuse large B cell lymphoma. Transl. Oncol. 6, 370–381 (2013).
Mostaghel, E. A. et al. Androgen receptor expression in mantle cell lymphoma: potential novel therapeutic implications. Exp. Hematol. 49, 34–38.e2 (2017).
Magri, F. et al. Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient’s risk. Endocr. Relat. Cancer 19, 463–471 (2012).
Xue, G. et al. A logic-incorporated gene regulatory network deciphers principles in cell fate decisions. eLife 12, RP88742 (2024).
Paczkó, M. et al. A neural network-based model framework for cell-fate decisions and development. Commun. Biol. 7, 323 (2024).
Qi, D. & Majda, A. J. Using machine learning to predict extreme events in complex systems. Proc. Natl Acad. Sci. 117, 52–59 (2020).
Snow, O., Lallous, N., Ester, M. & Cherkasov, A. Deep learning modeling of androgen receptor responses to prostate cancer therapies. Int. J. Mol. Sci. 21, 5847 (2020).
de Jong, A. C. et al. Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. Nat. Commun. 14, 1968 (2023).
Smith, A. M. Decoding immune kinetics: unveiling secrets using custom-built mathematical models. Nat. Methods 21, 744–747 (2024).
Wan, X. et al. Integrating spatial and single-cell transcriptomics data using deep generative models with SpatialScope. Nat. Commun. 14, 7848 (2023).
Yankeelov, T. E. et al. Designing clinical trials for patients who are not average. iScience 27, 108589 (2024).
